Mindray, YHLO, New Horizon Health, BGI Genomics and other IVD companies have won the Guruclub Greater China Best Listed Company Awards 2022

From December 15 to 22, the 7th "Guruclub Global Investment Carnival 2023" was grandly held. The result of Greater China Best Listed Companies has been announced and IVD companies Mindray Medical, United Imaging Healthcare, YHLO, New Horizon Health, BGI Genomics, GenePlus, and Qitan Technology were on the list.

With its purpose of "Global Vision, Betting on China", the evaluation covered all listed companies in Shanghai, Shenzhen, Hong Kong and the United States, aiming to create the most informative list of listed companies in the investment circle.

Annual Investment Value Award

Mindray Medical (300760.SZ)

United Imaging Healthcare(688271.SH)

About Mindray Medical

Firmly committed to Mindray’s mission, they employ advanced technologies and transform them into innovation adapted to clinical scenarios, bringing healthcare within reach with their sound R&D, marketing and service network. Mindray’s innovations cover a broad spectrum of medical industry. They offer integrated solutions that adapt to different departments to help healthcare providers boost efficiency and optimize management. Over the years, they have expanded their product lines and sought to serve more medical providers across the globe. 

About United Imaging Healthcare

Shanghai United Imaging Healthcare Co., Ltd. is dedicated to providing, developing and producing high-performance advanced medical imaging, radiotherapy equipment, life science instruments and offers intelligent digital solutions to customers worldwide. UIH is committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

Annual Social Responsibility Award

YHLO (688575.SH)

About YHLO

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers. In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575). As a national high-tech enterprise with many intellectual properties, YHLO’s mission is to "Focus on Healthcare, Better Life with Technology".

Annual Brand Value Award

New Horizon Health (06606.HK)

About New Horizon Health

Founded in 2015, New Horizon Health is the pioneer and market leader in China's cancer screening market focusing on early detection of high-incidence cancers. On February 18, 2021, New Horizon Health was successfully listed on the Stock Exchange of Hong Kong under the stock code of 6606.HK, becoming the "first cancer screening stock in China".

Annual Best IR Team

BGI Genomics (300676.SZ)

About BGI Genomics

BGI Genomics is the world's leading integrated solutions provider of precision medicine, now serving customers in more than 100 countries. They provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic sequencing and proteomic services and solutions across a broad range of applications spanning.

Annual Best Growing Unicorn Company

GenePlus

Qitan Technology

About GenePlus

Founded in 2015, GenePlus (Gene+) has built next-generation sequencing (NGS) clinical laboratories, genetic institutes and medical device bases on an industrial scale in Beijing, Suzhou and Shenzhen, and is a leading high-tech enterprise in oncology precision medicine in China. 

About Qitan Technology

Founded in 2016, Qitan Technology is the national high-tech enterprise with headquarters and production bases in Chengdu, and R&D centers in Beijing and Guangzhou. The company is committed to the research and development, manufacturing and application development of nanopore gene sequencers, supporting chips and reagents to meet the growing demand for gene sequencing.